Re: Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma
- PMID: 23141221
- DOI: 10.1016/j.juro.2012.08.170
Re: Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma
Comment on
-
Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.J Clin Oncol. 2012 May 10;30(14):1678-85. doi: 10.1200/JCO.2011.35.3524. Epub 2012 Apr 9. J Clin Oncol. 2012. PMID: 22493422 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
